Proposal was submitted by the Costa Rican President and the Health Minister to the Director-General of the WHO.
The proposal suggests creating a repository of information on diagnostic tests, devices, medication or vaccines, with free access or licensing on reasonable and affordable terms, in all member countries of the Organization.
It further urges the WHO to develop a memorandum of understanding to share this technology, and to promote its implementation with financial support from the public and private sectors, as well as from international organizations
Carlos Alvarado and Health Minister Daniel Salas have sent a proposal to Dr.
Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization
(WHO), suggesting that access to and use of intellectual property for
technologies to detect, prevent, control and treat the COVID-19 pandemic be provided.
letter put forward the creation of a repository of existing knowledge related
to diagnostic tests, devices, drugs or vaccines, which would be available in
the form of patents, both granted and in process; test data provided to
regulatory authorities, expert knowledge, cell lines (cell cultures),
copyrights and designs for the manufacture of diagnostic tests, devices, drugs
or vaccines. The aim is to
guarantee their free access and use by member countries.
Costa Rican Government proposes that the WHO «develop a concise memorandum
of understanding with the intention of inviting non-profit organizations,
industry and other relevant actors in the WHO member states to sign the
memorandum and enable these mechanisms for the exchange and use of information.
request is part of the arduous, inter-institutional effort and work that we
have embarked upon in Costa Rica. We know that extraordinary
work is required from all member states, but we have already
shown that we are capable of always going further,» said President
letter concludes by requesting that the Global Observatory on Health Research
and Development create a database on research and development activities
related to COVID-19, including estimates of the costs of clinical trials and
subsidies provided by governments and charities.